Advertisement

Topics

Fibrogen Announces Topline Results from Pooled Safety Analyses of Phase 3 Roxadustat Program

10:22 EDT 10 May 2019 | Speciality Pharma Journal

SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN) today announced topline results from the pooled safety analyses of the global Phase 3 program for roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI).  The global pivotal Phase 3 trials were conducted by FibroGen and collaboration partners AstraZeneca and Astellas Pharma, Inc., …

Original Article: Fibrogen Announces Topline Results from Pooled Safety Analyses of Phase 3 Roxadustat Program

NEXT ARTICLE

More From BioPortfolio on "Fibrogen Announces Topline Results from Pooled Safety Analyses of Phase 3 Roxadustat Program"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...